CD19 Antigens

Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.
Also Known As:
Antigens, CD19; B Cell Antigen CD19; CD19 Antigen; Antigen, CD19
Networked: 72 relevant articles (4 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Cheadle, Eleanor J: 4 articles (01/2014 - 05/2005)
2. Brentjens, Renier: 3 articles (04/2014 - 04/2011)
3. Sadelain, Michel: 3 articles (02/2014 - 09/2007)
4. Hawkins, Robert E: 3 articles (01/2014 - 05/2005)
5. Gilham, David E: 3 articles (01/2014 - 05/2005)
6. Stockmeyer, Bernhard: 3 articles (04/2011 - 07/2005)
7. Peipp, Matthias: 3 articles (04/2011 - 07/2005)
8. Fey, Georg H: 3 articles (04/2011 - 07/2005)
9. Bruenke, Joerg: 3 articles (04/2011 - 07/2005)
10. Maude, Shannon L: 2 articles (12/2015 - 12/2014)

Related Diseases

1. Neoplasms (Cancer)
2. Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
3. Leukemia
4. B-Cell Lymphoma (Lymphoma, B Cell)
5. B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
12/01/2014 - "CAR T cells can proliferate by 1000 times and differentiate in vivo by the CD19 antigen stimulation, therefore, kill the acute and chronic lymphocytic leukemia cells effectively. "
01/01/2014 - "T-cell therapy is one such area where recent trials using T cells genetically modified to express an antibody-based chimeric antigen receptor (CAR) targeted against the CD19 antigen have demonstrated impressive responses when adoptively transferred to patients with advanced chronic lymphocytic leukemia. "
09/15/1993 - "In the present study, we demonstrate the activation of T cells from patients with chronic lymphocytic leukemia (CLL) using bi-MABs against the CD3 and CD19 antigens (CD3 x CD19) in combination with monospecific, bivalent antibodies against the CD28 antigen. "
02/01/2014 - "Notable examples include the dramatic benefit of chimeric antigen receptor gene-modified T cells redirected towards B-cell lineage antigen CD19 in patients with chronic lymphocytic leukemia, and the impressive outcomes in the use of TCR gene-modified T cells redirected towards NY-ESO-1, a representative cancer-testis antigen, in patients with advanced melanoma and synovial cell sarcoma. "
12/15/1990 - "Notably, 82% of B-lineage chronic lymphocytic leukemias (CLLs), 82% of B-lineage hairy cell leukemias (HCLs), 86% of B-lineage non-Hodgkin's lymphomas (NHLs), and 29% of B-lineage acute lymphoblastic leukemias (ALLs) were CD40+. Quantitative analyses of the correlated expression of CD40 and other B-lineage differentiation antigens on fetal lymphoid precursor cells by multiparameter two-color/three-color flow cytometry, combined with analyses of sequential antigen expression on fluorescence-activated cell fluorescence activated cell sorter (FACS) isolated immunologically distinct fetal B-cell precursor subpopulations during in vitro proliferation and differentiation, provided evidence that the acquisition of CD40 antigen in human B-cell ontogeny occurs subsequent to the expression of CD10 and CD19 antigens but before the surface expression of CD20, CD21, CD22, CD24, and surface immunoglobulin M (sIgM). "

Related Drugs and Biologics

1. Immunotoxins (Immunotoxin)
2. Monoclonal Antibodies
3. Doxorubicin (Adriamycin)
4. Immunoglobulin Fab Fragments
5. Antigens
6. Antigen Receptors (Antigen Receptor)
7. Antibodies
8. Immunoglobulin G (IgG)
9. Neural Cell Adhesion Molecules (Neural Cell Adhesion Molecule)
10. CD28 Antigens

Related Therapies and Procedures

1. Immunotherapy
2. Drug Therapy (Chemotherapy)
3. Radioimmunotherapy
4. Heterologous Transplantation (Xenotransplantation)